A study identifies an increase in the tissue-protective factor HB-EGF during the initial stage of multiple sclerosis (MS), which is actively turned off as the disease worsens.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Linnerbauer, M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-024-01756-6 (2024).
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A. & Fugger, L. Nat. Rev. Immunol. 22, 734–750 (2022).
Kaufmann, M. et al. Nat. Neurosci. 25, 944–955 (2022).
Escartin, C. et al. Nat. Neurosci. 24, 312–325 (2021).
Hayakawa, K. et al. Nature 535, 551–555 (2016).
Mayo, L. et al. Nat. Med. 20, 1147–1156 (2014).
Koretsky, M. J. et al. Brain 146, 4486–4494 (2023).
Acknowledgements
K.E.A. and L.F. are supported by the Oak Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Jensen, L.T., Attfield, K.E. & Fugger, L. A repair pathway lost in multiple sclerosis provides a new drug opportunity. Nat Immunol 25, 385–386 (2024). https://doi.org/10.1038/s41590-024-01765-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-024-01765-5